<DOC>
	<DOCNO>NCT02395523</DOCNO>
	<brief_summary>This phase II study evaluate effectiveness hypofractionated proton beam therapy ( PBT ) Hepatocellular Carcinoma patient hepatitis B endemic area .</brief_summary>
	<brief_title>Hypofractionated Proton Beam Radiotherapy Inoperable Hepatocellular Carcinoma</brief_title>
	<detailed_description>The primary endpoint local progression free survival . The trial single arm phase II trial historical arm . The expected 3-year local progression free survival patient HCC patient treat proton beam therapy would 80 % . With power 80 % type I error level 10 % , evaluable 40 patient require reject null hypothesis true 3-year local progression free survival rate ≤65 % . Considering 10 % unevaluable patient due loss follow , total 45 eligible patient enrol .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Hepatocellular Carcinoma diagnose ( ) presence risk factor include hepatitis B C virus liver cirrhosis , serum afetoprotein ( AFP ) level great 200 IU/ml radiologically compatible feature HCC one CT/MRI/angiograms , ( ii ) presence risk factor include hepatitis B C virus liver cirrhosis , serum afetoprotein ( AFP ) level le 200 IU/ml , radiologically compatible feature HCC two CT/MRI/angiograms ( iii ) histological confirmation Inoperable HCC refusal surgery Recurrent/residual tumor local treatment ( local ablation therapy , transarterial chemoemobolization , etc ) , unsuitable/refusal treatment . Patients without evidence extrahepatic metastasis The large diameter tumor less 7cm , number tumor ≤2 The targeted tumor 2cm away alimentary tract ( i.e. , stomach , duodenum , esophagus , small large bowel ) No previous treatment target tumor form RT Liver function ChildPugh class A B7 ( ChildPugh score ≤7 ) Age ≥18 year Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) score Required Entry Laboratory Parameters WBC count ≥ 1,500/mm3 ; hemoglobin level ≥ 7.5 g/dL ; platelet count ≥ 30,000/mm3 ; adequate hepatic function ( total bilirubin ≤ 3.0 mg/dL ; AST ALT &lt; 5.0× upper limit normal ; uncontrolled ascites No serious comorbidities liver cirrhosis Signed informed consent form prior study entry There evidence extrahepatic metastasis . Age &lt; 18 year Liver function ChildPugh class B89 C ( ChildPugh score &gt; 7 ) Previous history form RT adjacent target tumor Poor performance status 2 4 Eastern Cooperative Oncology Group ( ECOG ) score Multicentric HCCs , except follow two condition : ( ) multinodular aggregate HCC could encompass single clinical target volume within single clinical target volume ; ( ii ) lesion target tumor judge control prior surgery and/or local ablation therapy . Pregnant breast feeding status Previous history uncontrolled malignancy within 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>